AlphaNooner - Dan Ahrens on What Could Move Markets This Week

Um, so maybe to start on the psychedelic side, I, I feel like, you know, some great quick stories that we've seen.

The Etai-Beckley acquisition going through is some great news.

Again, something that we've kind of obviously had on the radar for a while now, but great to see the completion of that deal getting done.

Um-

Yeah.

That's it, it's great for the space.

It's, um, just more, um, acceptance, um, and on a really big scale when you see a, a company like Eli Lilly taking over Etai-Beckley.

Some people were crying that, "Oh, I think it might've been worth more." That always happens with M&A deals.

I see it as a, a big positive and, um, mostly big reinforcement of big pharma needing to embrace alternative treatments and what we can see in psychedelic treatments of all types.

Mm-hmm.

And, um, it might tell a little bit about the future that we're probably gonna see more M&A, which in general, good thing for the space.

Yep, I was gonna ask.

I feel like it's been great to see.

I feel like, you know, the more M&A you see in the space, the more psychedelics are accepted as a real, um, sort of portfolio booster for these bigger psychedelic or bigger, um, pharmaceutical companies.

Just makes it easier for further acquisitions and ultimately further implementation, um, for these, you know, cures for people.

Um, or at least treatments, I think, um, is a good way to phrase it rather than cures.

But, um, yeah, some great stuff that we're seeing there.

Congrats to the Etai-Beckley team.

I know that takes a lot of time to get through.

Um, but ultimately see it as a very positive move, and we'll be interested to see if we see more M&A come through in the future.

Um, did also wanna highlight on another psychedelic story in the space that's moving.

Definium Therapeutics, uh, looks like they got their LSD candidate some fast track or breakthrough, um, therapy designation.

Uh, fantastic to see for the major depressive disorder.

So again, another, um, positive, I think, story building on the, the trend and story that we've talked about previously with, um, the government kind of coming in to produce kind of these, um, tailwinds to help the industry kind of open up, get these things reviewed, and get them to people who need it.

Um, and then yet just to mention, we're also pretty near...

Um, so maybe to start on the psychedelic side, I, I feel like, you know, some great quick stories that we've seen.

The Etai-Beckley acquisition going through is some great news.

Again, something that we've kind of obviously had on the radar for a while now, but great to see the completion of that deal getting done.

Um-

Yeah.

That's it, it's great for the space.

It's, um, just more, um, acceptance, um, and on a really big scale when you see a, a company like Eli Lilly taking over Etai-Beckley.

Some people were crying that, "Oh, I think it might've been worth more." That always happens with M&A deals.

I see it as a, a big positive and, um, mostly big reinforcement of big pharma needing to embrace alternative treatments and what we can see in psychedelic treatments of all types.

Mm-hmm.

And, um, it might tell a little bit about the future that we're probably gonna see more M&A, which in general, good thing for the space.

Yep, I was gonna ask.

I feel like it's been great to see.

I feel like, you know, the more M&A you see in the space, the more psychedelics are accepted as a real, um, sort of portfolio booster for these bigger psychedelic or bigger, um, pharmaceutical companies.

Just makes it easier for further acquisitions and ultimately further implementation, um, for these, you know, cures for people.

Um, or at least treatments, I think, um, is a good way to phrase it rather than cures.

But, um, yeah, some great stuff that we're seeing there.

Congrats to the Etai-Beckley team.

I know that takes a lot of time to get through.

Um, but ultimately see it as a very positive move, and we'll be interested to see if we see more M&A come through in the future.

Um, did also wanna highlight on another psychedelic story in the space that's moving.

Definium Therapeutics, uh, looks like they got their LSD candidate some fast track or breakthrough, um, therapy designation.

Uh, fantastic to see for the major depressive disorder.

So again, another, um, positive, I think, story building on the, the trend and story that we've talked about previously with, um, the government kind of coming in to produce kind of these, um, tailwinds to help the industry kind of open up, get these things reviewed, and get them to people who need it.

Um, and then yet just to mention, we're also pretty near...